Aquestive Therapeutics, Inc.
(NASDAQ : AQST)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
1.95%42.960.9%$1172.19m
LLYEli Lilly and Company
1.04%124.001.0%$1160.63m
JNJJohnson & Johnson
0.86%136.590.6%$960.96m
MRKMerck & Co., Inc.
1.12%80.720.6%$933.10m
BMYBristol-Myers Squibb Company
1.70%50.981.4%$779.97m
ABBVAbbVie, Inc.
1.60%80.012.2%$667.49m
AZNAstraZeneca PLC Sponsored ADR
1.27%40.951.3%$191.16m
NVSNovartis AG Sponsored ADR
0.30%90.780.2%$183.03m
GSKGlaxoSmithKline plc Sponsored ADR
0.03%40.550.2%$135.60m
NVONovo Nordisk A/S Sponsored ADR Class B
0.28%49.800.1%$67.28m
SNYSanofi Sponsored ADR
-0.36%41.180.2%$36.78m
LCILannett Company, Inc.
0.64%9.4136.7%$16.84m
AKTXAkari Therapeutics Plc Sponsored ADR
-2.70%1.801.7%$0.06m
EPIXESSA Pharma Inc
1.96%3.640.1%$0.04m

Company Profile

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The company also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.